- Conditions
- Germ Cell Tumor
- Interventions
- Bleomycin (active name: Bleomycin Sulfate), Etoposide, Cisplatin, Pegylated G-CSF (Pegfilgrastim), Filgrastim
- Drug
- Lead sponsor
- University of Sydney
- Other
- Eligibility
- 11 Years to 50 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2029
- U.S. locations
- 21
- States / cities
- Downey, California • Loma Linda, California • Long Beach, California + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 262
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hodgkin Disease
- Interventions
- Filgrastim SD/01, Adriamycin, Bleomycin, Vinblastine, DTIC
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Interventions
- doxorubicin hydrochloride, cyclophosphamide, bevacizumab, paclitaxel, filgrastim, pegfilgrastim, radiation therapy, tamoxifen citrate, aromatase inhibition therapy
- Drug · Biological · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Leukemia, Lymphoma
- Interventions
- Pegfilgrastim, Rituximab, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hodgkin Lymphoma
- Interventions
- brentuximab vedotin, doxorubicin, vinblastine, dacarbazine, G-CSF, nivolumab
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 55
- States / cities
- Fountain Valley, California • Aurora, Colorado • Colorado Springs, Colorado + 48 more
- Conditions
- Sarcoma
- Interventions
- filgrastim, pegfilgrastim, docetaxel, gemcitabine hydrochloride
- Biological · Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 60
- States / cities
- Los Angeles, California • Hartford, Connecticut • New Britain, Connecticut + 47 more
- Conditions
- Hodgkin's Disease, Lymphoma
- Interventions
- bendamustine hcl
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer
- Interventions
- Pre operativeTrastuzumab, ABI-007 (Abraxane), Vinorelbine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Lymphoma
- Interventions
- Pegfilgrastim, Loratadine, Placebo, Questionnaires
- Drug · Other · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neutropenia
- Interventions
- SPI-2012, Pegfilgrastim, Docetaxel, Cyclophosphamide
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 10
- States / cities
- Glendale, Arizona • Scottsdale, Arizona • Fresno, California + 7 more
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of the Breast, Neoplasms, Breast, Tumors, Breast
- Interventions
- Eribulin, Doxorubicin, Cyclophosphamide, Pegfilgrastim
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Madison, Wisconsin
- Conditions
- Healthy
- Interventions
- CHS-1701, Pegfilgrastim
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Cypress, California • Cincinnati, Ohio • San Antonio, Texas + 1 more
- Conditions
- Leukemia
- Interventions
- Rituximab, Imatinib, Cyclophosphamide, Doxorubicin, Mesna, VSLI, Solu-Medrol, Methotrexate, Ara-C, G-CSF, Pegfilgrastim, Dexamethasone
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer, Metastatic Breast Cancer
- Interventions
- Lapatinib, Doxorubicin, Cyclophosphamide, Docetaxel, Pegfilgrastim, Filgrastim, Dexamethasone, Trastuzumab
- Drug
- Lead sponsor
- George Albert Fisher
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- San Jose, California • Stanford, California
- Conditions
- Richter's Transformation, Leukemia
- Interventions
- Oxaliplatin, Fludarabine, Cytarabine, Rituximab, Pegfilgrastim
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Soft-tissue Sarcoma
- Interventions
- Camsirubicin
- Drug
- Lead sponsor
- Monopar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Santa Monica, California • Seattle, Washington
- Conditions
- Triple-negative Breast Cancer
- Interventions
- Carboplatin, Docetaxel, Pembrolizumab, Pegfilgrastim
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 9
- States / cities
- Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 4 more
- Conditions
- Infant-Type Hemispheric Glioma
- Interventions
- Alectinib, Entrectinib, Surgery, Cyclophosphamide, Etoposide, Carboplatin, Filgrastim, Pegfilgrastim
- Drug · Procedure · Biological
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 60 Months
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- doxorubicin hydrochloride, cyclophosphamide, bevacizumab, paclitaxel, gemcitabine hydrochloride, laboratory biomarker analysis, pegfilgrastim
- Drug · Biological · Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Breast Cancer, Neutropenia
- Interventions
- F-627, Neulasta
- Drug
- Lead sponsor
- EVIVE Biotechnology
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Leukemia, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Lymphoblastic Lymphoma
- Interventions
- Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide, Ofatumumab, Pegfilgrastim, Rituximab, Vincristine Sulfate Liposome
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer, Neutropenia
- Interventions
- F-627, Neulasta® (pegfilgrastim)
- Drug
- Lead sponsor
- EVIVE Biotechnology
- Industry
- Eligibility
- 18 Years to 74 Years · Female only
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Anderson, Indiana
- Conditions
- Breast Cancer
- Interventions
- trastuzumab, docetaxel and carboplatin in dose dense regimen
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Metastatic Breast Cancer
- Interventions
- LY2523355, ixabepilone, pegfilgrastim, filgrastim
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 12
- States / cities
- Fort Myers, Florida • Pensacola, Florida • Gainesville, Georgia + 9 more